Managing adverse events in the use of bevacizumab and chemotherapy.
AffiliationChristie Hospital NHS Foundation Trust, Manchester.
MetadataShow full item record
AbstractThe anti-angiogenic agent bevacizumab (Avastin) has received regulatory approval for the treatment of metastatic breast cancer (MBC) in combination with the taxane chemotherapy agent paclitaxel. A range of side-effects associated with this agent have been identified across different tumour types; these are known to differ from those frequently reported with chemotherapy agents. This article is part one of a two-part literature review that was conducted to provide insight into the range, frequency and severity of adverse events that arise specifically in breast cancer when bevacizumab is combined with cytotoxic chemotherapy. PubMed and the websites of oncology conferences were searched to identify studies of bevacizumab plus chemotherapy in patients with MBC. Seventeen studies met the search criteria, including 3,836 bevacizumab-treated patients. Side-effects associated with bevacizumab included hypertension, proteinuria, thromboembolic events, bleeding and cardiac toxicity. Part two of the series will appear in the next issue of BJN.
CitationManaging adverse events in the use of bevacizumab and chemotherapy., 18 (6):351-6, 358 Br J Nurs
JournalBritish Journal of Nursing
- Adverse events in bevacizumab and chemotherapy: patient management.
- Authors: Blowers E, Hall K
- Issue date: 2009 Apr 9-22
- Safety of bevacizumab in patients with metastatic breast cancer.
- Authors: Hamilton EP, Blackwell KL
- Issue date: 2011
- Managing patients treated with bevacizumab combination therapy.
- Authors: Gordon MS, Cunningham D
- Issue date: 2005
- Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
- Authors: Hurwitz H, Saini S
- Issue date: 2006 Oct
- Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
- Authors: Shih T, Lindley C
- Issue date: 2006 Nov